The discovery of oncogenic driver mutations of the EGFR gene and the approval of EGFR inhibitors have revolutionized the targeted individualized treatment approach in non-small-cell lung cancer (NSCLC) (29). This evidence concerns the gene EGFR and non-small cell lung carcinoma.